Pfizer Ltd. (PFIZER) fundamentals
Pfizer Ltd. is a listed company in Pharmaceuticals & Biotechnology, part of the Healthcare sector, listed on the NSE as PFIZER (ISIN INE182A01018). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Pfizer Ltd. does
Pfizer Limited (Pfizer) is an India-based multinational pharmaceutical company focusing on therapy in four business categories, namely, Vaccines, Hospitals, Internal Medicine, and Inflammation and Immunology. Pfizer’s Vaccines Division focuses on Prevenar 13, a Pneumococcal Conjugate Vaccine approved for administering to individuals of all ages against pneumococcal disease, an infection caused by streptococcus pneumoniae bacteria. Internal Medicine portfolio includes approximately 17 specialties and seven therapy areas, including respiratory, multivitamin and multimineral, gastrointestinal, pain, neuroscience, cardiovascular and women’s healthcare. Pfizer Hospital Business Unit focuses on providing advanced anti-infectives to institutions such as hospitals and nursing homes. Inflammation and Immunology focuses on discovering and developing novel therapeutics for chronic autoimmune diseases. Its brands include Prevenar13, CorexDX, Dolonex, Enbrel, Becosules and Folvite, among others.
Valuation and market data
| Last close | ₹4060.20 |
|---|---|
| Market capitalisation | ₹18,574 crore |
| Enterprise value | ₹18,563 crore |
| P/E (TTM) | 25.71 |
| Price to book | 4.42 |
| Price to sales (TTM) | 4.05 |
| Book value per share | ₹918.73 |
| Dividend yield | 184.72% |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Listed since | Wed Apr 28 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹2,708 crore | ₹976 crore | ₹722 crore | 157.92 |
| Mar 2025 | ₹2,454 crore | ₹1,016 crore | ₹768 crore | 167.79 |
| Mar 2024 | ₹2,374 crore | ₹746 crore | ₹551 crore | 119.22 |
| Mar 2023 | ₹2,526 crore | ₹824 crore | ₹624 crore | 136.38 |
Figures are as reported (standalone), in ₹ crore.
Shareholding pattern
As of Jun 2026:
| Promoters | 63.9% |
|---|---|
| Foreign institutions (FII) | 1.6% |
| Mutual funds | 12.7% |
| Other domestic institutions | 5.1% |
| Retail and others | 16.6% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.